The global APOL1-mediated kidney disease market is poised for substantial expansion, with projections indicating a remarkable increase from USD 3779.9 million in 2023 to an estimated USD 5753.9 million by 2033. This impressive growth represents a Compound Annual Growth Rate (CAGR) of 4.3%, underscoring a critical demand for innovative therapies targeting the underlying causes of this debilitating condition.
APOL1-mediated kidney disease, which disproportionately affects certain populations, poses significant health challenges and demands urgent attention. As research advances and our understanding of this complex condition deepens, the need for effective treatment options has never been greater. The anticipated market growth reflects a strong commitment from the pharmaceutical and biotechnology sectors to develop therapies that not only address symptoms but also target the root causes of this disease.
The projected market expansion presents a unique opportunity for stakeholders to invest in and prioritize the development of novel therapeutic solutions. As awareness of APOL1-mediated kidney disease increases, so does the potential for breakthroughs that could transform patient outcomes and improve quality of life.
Key Takeaways from APOL1 Mediated kidney Diseases Market Study
- Chronic kidney diseases account for more than 95% of all the APOL1 mediated diseases. Increasing prevalence of hypertension associated kidney diseases will increase treatment needs over the forecast period
- North America accounts for over 3/4th of the global market. High prevalence of the disease among people with African American ancestry makes North America the leader in this market
- Pipeline drugs under development are targeted to be launched in the U.S., catapulting it as a highly lucrative pocket
- Key players are focusing on extensive research and development for targeted therapy towards APOL1
- The COVID-19 outbreak did not have any impact on the APOl1 mediated treatment market. All patients with indications like end stage kidney disorders were attended amidst COVID-19 due to the severity of kidney disease
“Increasing research and development for discovery of underlying cause of APOL1 mediated kidney disease and its targeted therapy will propel the market growth in the future,” says FMI analyst
Growing Need for Market Insights: Access Our Full Report for Thorough Analysis and Trends!
Market Competition:
The APOL1-mediated kidney disease market is highly competitive, characterized by several prominent industry players actively involved in its development. Leading companies such as Vertex Pharmaceuticals Incorporated, Ionis Pharmaceuticals, AstraZeneca, Pfizer Inc., Novartis AG, GlaxoSmithKline plc, Merck & Co., Inc., Sanofi S.A., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, and Roche Holding AG are investing significantly in advancing treatments for APOL1-mediated kidney disease (AMKD).
Recent market developments include:
Major industry players are employing organic growth strategies such as acquisitions, mergers, partnerships, and collaborations to broaden their product offerings, thereby driving growth in the global APOL1-mediated kidney disease market.
- On November 4, 2022, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) partnered with basketball Hall-of-Famer Alonzo Mourning to launch “Power Forward,” an educational initiative aimed at raising awareness about APOL1-mediated kidney disease (AMKD) and emphasizing the importance of early diagnosis and genetic testing.
- In July 2022, AstraZeneca collaborated with the Indian Society of Nephrology to establish the Chronic Kidney Disease Academy, focusing on enhancing knowledge and treatment practices related to chronic kidney diseases.
Key Segments Profiled In The Apol1 Mediated Kidney Disease Market:
By Indication:
- Chronic Kidney Disease
- Focal segmental glomerulosclerosis (FSGS)
- Human immunodeficiency virus (HIV)-associated Nephropathy
- Hypertension-associated Kidney Disease
- End-Stage Kidney Disease
Region
- North America (U.S.)
- Europe
- MEA
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
